ONCY vs. ACIU, CGC, CADL, BNTC, CCCC, FHTX, URGN, LFCR, ATAI, and ELDN
Should you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include AC Immune (ACIU), Canopy Growth (CGC), Candel Therapeutics (CADL), Benitec Biopharma (BNTC), C4 Therapeutics (CCCC), Foghorn Therapeutics (FHTX), UroGen Pharma (URGN), Lifecore Biomedical (LFCR), Atai Life Sciences (ATAI), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical products" industry.
Oncolytics Biotech vs.
AC Immune (NASDAQ:ACIU) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, community ranking, dividends and earnings.
Oncolytics Biotech has lower revenue, but higher earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.
AC Immune's return on equity of -28.26% beat Oncolytics Biotech's return on equity.
AC Immune presently has a consensus price target of $12.00, suggesting a potential upside of 347.76%. Oncolytics Biotech has a consensus price target of $4.00, suggesting a potential upside of 405.69%. Given Oncolytics Biotech's higher possible upside, analysts plainly believe Oncolytics Biotech is more favorable than AC Immune.
AC Immune has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.
51.4% of AC Immune shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 4.6% of AC Immune shares are held by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, AC Immune and AC Immune both had 1 articles in the media. AC Immune's average media sentiment score of 1.05 beat Oncolytics Biotech's score of -0.66 indicating that AC Immune is being referred to more favorably in the media.
AC Immune received 102 more outperform votes than Oncolytics Biotech when rated by MarketBeat users. However, 68.12% of users gave Oncolytics Biotech an outperform vote while only 62.47% of users gave AC Immune an outperform vote.
Summary
AC Immune beats Oncolytics Biotech on 8 of the 13 factors compared between the two stocks.
Get Oncolytics Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncolytics Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:ONCY) was last updated on 1/21/2025 by MarketBeat.com Staff
